市場調查報告書

消化器官治療藥的全球市場 - 成長率,趨勢,預測:2019年∼2024年

Gastrointestinal Therapeutics Market - Growth, Trends, and Forecast (2019 - 2024)

出版商 Mordor Intelligence LLP 商品編碼 704952
出版日期 內容資訊 英文 113 Pages
商品交期: 2-3個工作天內
價格
Back to Top
消化器官治療藥的全球市場 - 成長率,趨勢,預測:2019年∼2024年 Gastrointestinal Therapeutics Market - Growth, Trends, and Forecast (2019 - 2024)
出版日期: 2019年06月01日內容資訊: 英文 113 Pages
簡介

胃腸道治療市場主要由導致胃腸疾病的生活方式改變所推動。根據2017年全國健康訪談調查(National Health Interview Survey),美國有1530萬成年人被診斷患有潰瘍。

本報告依藥物類型·劑型·適應症及地區別提供全球消化器官治療藥市場分析,提供競爭情形,主要企業的簡介等資訊。

第1章 簡介

第2章 調查手法

第3章 摘要整理

第4章 市場動態

  • 市場概要
  • 推動市場要素
  • 阻礙市場要素
  • 波特的五力分析

第5章 市場區隔

  • 各藥物類型
    • 製酸藥
    • 便秘藥
    • 止瀉藥
    • 制吐藥
    • 抗潰瘍藥
    • 其他
  • 各劑型
    • 口服藥
    • 非口服藥
    • 其他
  • 各適應症
    • 潰瘍性大腸炎
    • 大腸激躁症
    • 克隆氏症
    • 麩質過敏症
    • 腸胃炎
    • 其他
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東·非洲
    • 南美

第6章 競爭情形

  • 企業簡介
    • Abbott Laboratories
    • Allergan PLC
    • Astellas Pharma Inc.
    • AstraZeneca
    • Bayer AG
    • GlaxoSmithKline PLC
    • Janssen Pharmaceuticals, Inc. (Johnson & Johnson)
    • Pfizer Inc.
    • AbbVie, Inc.
    • 武田藥品工業

第7章 市場機會及未來趨勢

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 62814

Market Overview

The gastrointestinal therapeutics market is majorly driven by lifestyle changes leading to GI diseases. According to the National Health Interview Survey, 2017, 15.3 million adults were diagnosed with ulcers in the US. Other driving factors include rising surgical treatments and hospitalizations due to GI diseases and increasing R&D investments by biopharmaceutical companies in developing biologics and biosimilars. However, an increasing number of patent expirations and other factors such as physiological, behavioral, psychosocial, and socio-environmental risk factors, also restrict the populations from reporting the diseases early which reflects low awareness as well as an economic burden, restring the growth of the gastrointestinal therapeutics market.

Scope of the Report

Gastrointestinal disorders are the term used to refer to any condition or disease that occurs within the gastrointestinal tract. The gastrointestinal tract (also called the GI tract) is a series of hollow organs that form a long continuous passage from our mouth to our anus. The organs that make up our GI tract are our mouth, esophagus, stomach, small intestine, large intestine, and anus. Gastrointestinal (GI) complaints are common among infants, children, and adults, which results from the reflux of stomach contents into the esophagus. The upper GI tract has shown highly prevalent disorders in specialized and primary cares. It constitutes a large proportion of outpatients and frequent hospital visits globally.

Key Market Trends

Inflammatory ulcerative colitis holds significant market share

The inflammatory ulcerative colitis disease is often a relapsing and remitting disease. The disease often deals with lifelong treatment therapies. However, the current treatment options have several adverse effects, poor efficacy profiles, and sometimes, the cost of the drug is highly expensive, which makes this segment lucrative for the biopharmaceutical companies. Some of the traditional classes of drugs are helpful for inflammatory bowel disease (IBD) including 5-aminosalicylic acid, corticosteroids, and immune-modulating drugs. Biologic drugs have also been explored in the past two decades, with several being marketed, which include anti-TNF drugs, immunosuppressive interleukins, and anti-interleukin antibodies. As per Merck & Co. Inc., 2018, apart from the presence of diverse medication facilities, still one-third of the overall patient population suffering from UC ultimately require surgery. Takeda Pharmaceuticals, Jassen Pharmaceuticals, Pfizer are among the major global companies that have established themselves well in the treatment of inflammatory ulcerative colitis.

The Asia Pacific is the fastest growing region in the Global Gastrointestinal Therapeutics Market

The Asian countries have shown the similar trend of growth in recent years as compared to western developed markets particularly owing to increasing economic growth along with privatization, competitive site experience, technological expertise, infrastructure, and scale to manage large-scale clinical trials across India, China, Japan, South Korea, and others. The stomach related diseases have shown similar growth characteristics (incidence and prevalence) to western countries and thus the data of clinical trials are routinely accepted as part of US Food and Drug Administration (FDA) and European Medicines Agency (EMA) regulatory authorities. The unmet medical need and potential market opportunity have accelerated the partnerships with Asian pharmaceutical companies for development and commercial potential in the growth of the pharmaceutical business.

Competitive Landscape

There is a rising trend towards the development of targeted therapeutics products by the companies. In the process of finding innovative methods, the companies are majorly expanding their pipeline and product portfolio through collaborations with specialized companies in the gastrointestinal therapeutics and devices. For instance, In July 2018: HiFiBiO Therapeutics collaborated with Takeda, in a multi-target agreement for the discovery of breakthrough antibody therapies to potentially treat a variety of gastrointestinal diseases, cancers, and other disorders. The major players in the market include Abbott, Allergan, GlaxoSmithKline PLC, Pfizer, Takeda Pharmaceutical Company Limited, among others.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Prevalence of GI Diseases
    • 4.2.2 Increasing Investments in R&D by Pharmaceutical Companies
  • 4.3 Market Restraints
    • 4.3.1 Rising Socio-Economic Burden Associated with Gastrointestinal Disorders
    • 4.3.2 Increasing Number of Patent Expirations
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 Drug Type
    • 5.1.1 Antacids
    • 5.1.2 laxatives
    • 5.1.3 Antidiarrheal agents
    • 5.1.4 Antiemetics
    • 5.1.5 Antiulcer agents
    • 5.1.6 Others
  • 5.2 Dosage Form
    • 5.2.1 Oral
    • 5.2.2 Parenteral
    • 5.2.3 Others
  • 5.3 Application
    • 5.3.1 Inflammatory Ulcerative Colitis
    • 5.3.2 Irritable Bowel Syndrome
    • 5.3.3 Crohn's Disease
    • 5.3.4 Celiac Disease
    • 5.3.5 Gastroenteritis
    • 5.3.6 Others
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 US
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 UK
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East and Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle East and Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Abbott Laboratories
    • 6.1.2 Allergan PLC
    • 6.1.3 Astellas Pharma Inc.
    • 6.1.4 AstraZeneca
    • 6.1.5 Bayer AG
    • 6.1.6 GlaxoSmithKline PLC
    • 6.1.7 Janssen Pharmaceuticals, Inc. (Johnson & Johnson)
    • 6.1.8 Pfizer Inc.
    • 6.1.9 AbbVie, Inc.
    • 6.1.10 Takeda Pharmaceutical Company Limited

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Back to Top